Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data Satellos Bioscience Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
Research and development
14.4
18.4
Operating income
-20.4
-26.5
Interest income
1
1.36
Pre-tax income
-20.6
-24.7
Income tax
0.17
Net income
-20.6
-24.9
EPS, basic
-2.16
-1.70
EPS, diluted
-2.16
-1.70
Balance sheet
FY2025
FY2025
Cash and equivalents
40.1
9.8
Short-term investments
8.48
17.9
Total current assets
50.7
31.9
Property, plant and equipment
0
0.01
Total assets
50.7
31.9
Accounts payable
3.58
4.11
Total current liabilities
3.58
4.11
Total liabilities
3.58
4.11
Retained earnings
-57.1
-82
Total equity
47.2
27.8
Total liabilities and equity
50.7
31.9
Cash flow statement
FY2025
FY2025
Net income
-20.6
-24.9
Cash from operations
-18.3
-23.6
Capital expenditures
-0
-0.01
Cash from investing
4.66
-9.42
Stock issued
30.1
Cash from financing
37.6
2.24
Exchange rate effect
-0.59
0.5
Net change in cash
23.4
-30.3
Free cash flow
-18.3
-23.6
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $8.70 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-60.2%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
-37.2%
Total assets vs the same period a year earlier. Only from a positive base.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
7.77x
Current assets / current liabilities.
Quick ratio
6.75x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
6.75x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
12.9%
Total liabilities / total assets.
Working capital
$27.8M
Current assets - current liabilities.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$1.70
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$1.70
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$184.6M
Share price x shares outstanding.
Enterprise value
$156.9M
Market cap + total debt - cash - short-term investments.
FCF yield
-12.8%
Free cash flow / market cap.
Earnings yield
-13.5%
Net income / market cap (the inverse of P/E).
Was Satellos Bioscience Inc. profitable in fiscal 2025?
No. It reported a net loss of $24.9M.
How much free cash flow did Satellos Bioscience Inc. generate in fiscal 2025?
Cash from operations of $23.6M minus capital expenditures of $6.0K left free cash flow of -$23.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.